Literature DB >> 24676840

Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.

Nan Qin1, Aguirre A de Cubas, Ruben Garcia-Martin, Susan Richter, Mirko Peitzsch, Mario Menschikowski, Jacques W M Lenders, Henri J L M Timmers, Massimo Mannelli, Giuseppe Opocher, Matina Economopoulou, Gabriele Siegert, Triantafyllos Chavakis, Karel Pacak, Mercedes Robledo, Graeme Eisenhofer.   

Abstract

Pheochromocytomas and paragangliomas (PPGLs) are catecholamine-producing chromaffin cell tumors with diverse phenotypic features reflecting mutations in numerous genes, including MYC-associated factor X (MAX). To explore whether phenotypic differences among PPGLs reflect a MAX-mediated mechanism and opposing influences of hypoxia-inducible factor (HIF)s HIF2α and HIF1α, we combined observational investigations in PPGLs and gene-manipulation studies in two pheochromocytoma cell lines. Among PPGLs from 140 patients, tumors due to MAX mutations were characterized by gene expression profiles and intermediate phenotypic features that distinguished these tumors from other PPGLs, all of which fell into two expression clusters: one cluster with low expression of HIF2α and mature phenotypic features and the other with high expression of HIF2α and immature phenotypic features due to mutations stabilizing HIFs. Max-mutated tumors distributed to a distinct subcluster of the former group. In cell lines lacking Max, re-expression of the gene resulted in maturation of phenotypic features and decreased cell cycle progression. In cell lines lacking Hif2α, overexpression of the gene led to immature phenotypic features, failure of dexamethasone to induce differentiation and increased proliferation. HIF1α had opposing actions to HIF2α in both cell lines, supporting evolving evidence of their differential actions on tumorigenic processes via a MYC/MAX-related pathway. Requirement of a fully functional MYC/MAX complex to facilitate differentiation explains the intermediate phenotypic features in tumors due to MAX mutations. Overexpression of HIF2α in chromaffin cell tumors due to mutations affecting HIF stabilization explains their proliferative features and why the tumors fail to differentiate even when exposed locally to adrenal steroids.
© 2014 UICC.

Entities:  

Keywords:  HIF1α; HIF2α; MAX; phenylethanolamine N-methyltransferase; pheochromocytoma and paraganglioma

Mesh:

Substances:

Year:  2014        PMID: 24676840     DOI: 10.1002/ijc.28868

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  A defined, controlled culture system for primary bovine chromaffin progenitors reveals novel biomarkers and modulators.

Authors:  Jimmy Masjkur; Ian Levenfus; Sven Lange; Carina Arps-Forker; Steve Poser; Nan Qin; Vladimir Vukicevic; Triantafyllos Chavakis; Graeme Eisenhofer; Stefan R Bornstein; Monika Ehrhart-Bornstein; Andreas Androutsellis-Theotokis
Journal:  Stem Cells Transl Med       Date:  2014-05-22       Impact factor: 6.940

Review 2.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

3.  The microenvironment induces collective migration in SDHB-silenced mouse pheochromocytoma spheroids.

Authors:  Vanessa D'Antongiovanni; Serena Martinelli; Susan Richter; Letizia Canu; Daniele Guasti; Tommaso Mello; Paolo Romagnoli; Karel Pacak; Graeme Eisenhofer; Massimo Mannelli; Elena Rapizzi
Journal:  Endocr Relat Cancer       Date:  2017-10       Impact factor: 5.678

Review 4.  PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS.

Authors:  Garima Gupta; Karel Pacak
Journal:  Endocr Pract       Date:  2017-03-23       Impact factor: 3.443

Review 5.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

6.  MIL-125-based nanocarrier decorated with Palladium complex for targeted drug delivery.

Authors:  Mojtaba Bagherzadeh; Moein Safarkhani; Mahsa Kiani; Fatemeh Radmanesh; Hossein Daneshgar; Amir Mohammad Ghadiri; Fahimeh Taghavimandi; Yousef Fatahi; Nahid Safari-Alighiarloo; Sepideh Ahmadi; Navid Rabiee
Journal:  Sci Rep       Date:  2022-07-15       Impact factor: 4.996

7.  Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment.

Authors:  Magnus Zethoven; Luciano Martelotto; Andrew Pattison; Blake Bowen; Shiva Balachander; Aidan Flynn; Fernando J Rossello; Annette Hogg; Julie A Miller; Zdenek Frysak; Sean Grimmond; Lauren Fishbein; Arthur S Tischler; Anthony J Gill; Rodney J Hicks; Patricia L M Dahia; Roderick Clifton-Bligh; Karel Pacak; Richard W Tothill
Journal:  Nat Commun       Date:  2022-10-21       Impact factor: 17.694

Review 8.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

9.  Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.

Authors:  Christina Pamporaki; Barbora Hamplova; Mirko Peitzsch; Aleksander Prejbisz; Felix Beuschlein; Henri J L M Timmers; Martin Fassnacht; Barbara Klink; Maya Lodish; Constantine A Stratakis; Angela Huebner; Stephanie Fliedner; Mercedes Robledo; Richard O Sinnott; Andrzej Januszewicz; Karel Pacak; Graeme Eisenhofer
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

10.  Mild chronic hypoxia-induced HIF-2α interacts with c-MYC through competition with HIF-1α to induce hepatocellular carcinoma cell proliferation.

Authors:  Han Mu; Ge Yu; Huikai Li; Mengmeng Wang; Yunlong Cui; Ti Zhang; Tianqiang Song; Changfu Liu
Journal:  Cell Oncol (Dordr)       Date:  2021-08-02       Impact factor: 7.051

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.